To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.
This study will sample urine provided by bladder cancer patients as part of their normal
routine surveillance screening. No additional effort will be required from the patients and
only modest additional effort from the study staff. Some de-identified patient medical
information may also be requested, including concominant medications, relevant current or
previous diseases, prior bladder cancer interventions and other relevant information to
ensure there are no interfering substances or other confounders that could affect study
results. There is no risk to patients as the normal diagnostics for bladder cancer will be
|Overal Status||Start Date||Phase||Study Type|
|Recruiting||February 8, 2021||Observational [Patient Registry]|
Primary Outcome 1 - Measure: Successful identification of bladder tumor biomarkersBiomarkers in Patients Under Active BCa Surveillance
Primary Outcome 1 - Time Frame: Up to 1 year
1. Male and female patients ≥ 18 years
2. Previous bladder cancer diagnosis; any stage and histological type, undergoing
3. Patients with suspected bladder tumor undergoing surveillance cystoscopy
4. Patients must provide written Informed Consent.
1. Patients unable or unwilling to sign the informed consent
2. Age < 18 years
3. Known HIV/HCV/HBV (information from clinical history).
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: Accepts Healthy Volunteers
Name: Rodney Brenneman
|Providence Saint John's Health Center and the Saint John's Cancer Institute
Santa Monica, California 90404
Lisa van Kreuningen, M.S.